Background Elevated plasma level of hs CRP ( >3 g/mL) is known to be associated with significant coronary artery disease. However, there have been limited data whether the association of hs CRP and the angiographic and long term clinical outcomes of the patients (pts) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). Methods The study population consisted of 1838 consecutive patients (pts) undergoing PCI enrolled from November 2005 to June 2008. We compared angiographic and major clinical outcomes of pts in high hs CRP group (>3 g/mL, n= 892 pts, 48.5%) with those of Control group (��� 3 g/mL, n= 946 pts, 51.5%) up to 2 years. Results The baseline clinical and procedural characteristics showed that high hs CRP group had more elderly and smoker, more STEMI and NSTEMI, and lower left ventricular ejection fraction (LVEF). Six-month angiographic outcomes were similar between two groups and pts of high hs CRP group showed higher cumulative cardiac death (CD) and total major cardiac adverse event (MACE) up to 2 years compared with control group. High hsCRP was an independent risk factor of CD (Adjusted OR: 11.290, 95% CI:3.847-33.133, p-value=0.001) and total MACE up to 2 years (Adjusted OR: 2.712, 95% CI:1.854-3.967, p-value=0.001) (Table). Conclusions In our study, NT-proBNP level tended to be associated with CD and total MACE up to 2 years and hs CRP was an independent predictor for total MACE. We suggest that elevated hs CRP may play an important and sensitive role in long term clinical outcome in pts undergoing PCI.